We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · August 10, 2022

Relugolix vs Placebo for Endometriosis-Associated Pain

The Lancet


Additional Info

The Lancet
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet 2022 Jun 18;399(10343)2267-2279, LC Giudice, S As-Sanie, JC Arjona Ferreira, CM Becker, MS Abrao, BA Lessey, E Brown, K Dynowski, K Wilk, Y Li, V Mathur, QA Warsi, RB Wagman, NP Johnson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading